Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

SHA:688266 Revenue

Suzhou Zelgen Biopharmaceuticals had revenue of 217.79M CNY in the quarter ending September 30, 2025, with 51.85% growth. This brings the company's revenue in the last twelve months to 742.28M, up 51.97% year-over-year. In the year 2024, Suzhou Zelgen Biopharmaceuticals had annual revenue of 532.95M with 37.91% growth.

• Revenue (ttm): 742.28M
• Revenue Growth: +51.97%
• P/S Ratio: 37.77
• Revenue / Employee: 815.69K
• Employees: 910
• Market Cap: 28.03B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	532.95M	146.52M	37.91%
Dec 31, 2023	386.44M	84.13M	27.83%
Dec 31, 2022	302.31M	111.94M	58.81%
Dec 31, 2021	190.36M	162.70M	588.19%
Dec 31, 2020	27.66M	-	-